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Abstract: Porcine reproductive and respiratory syndrome viruses (PRRSV) are responsible for one of
the most economically important diseases affecting the global pig industry. On-farm high-efficiency
particulate air (HEPA) filtration systems can effectively reduce airborne transmission of PRRSV
and the incidence of PRRS, but they are costly, and their adoption is limited. Therefore, there is a
need for low-cost alternatives, such as antimicrobial filters impregnated with antiviral nanoparticles
(AVNP). During the past 10 years, tailored intermetallic/multi-elemental AVNP compositions have
demonstrated effective performance against human viruses. In this study, a panel of five AVNP was
evaluated for viricidal activity against PRRSV. Three AVNP materials: AVNP2, copper nanoparticles
(CuNP), and copper oxide nanoparticles (CuONP), were shown to exert a significant reduction
(>99.99%) in virus titers at 1.0% (w/v) concentration. Among the three, CuNP was the most effective
at lower concentrations. Further experiments revealed that AVNP generated significant reductions
in viral titers within just 1.5 min. For an optimal reduction in viral titers, direct contact between
viruses and AVNP was required. This was further explained by the inert nature of these AVNP,
where only negligible leaching concentrations of Ag/Cu ions (0.06–4.06 ppm) were detected in AVNP
supernatants. Real-time dynamic light scatting (DLS) and transmission electron microscopic (TEM)
analyses suggested that the mono-dispersive hydrodynamic behavior of AVNPs may have enhanced
their antiviral activity against PRRSV. Collectively, these data support the further evaluation of these
AVNP as candidate nanoparticles for incorporation into antimicrobial air-filtration systems to reduce
transmission of PRRSV and other airborne pathogens.
Keywords: porcine reproductive and respiratory syndrome virus; antiviral nanoparticle; viricidal
efficacy; staphylococcus aureus
1. Introduction
Porcine reproductive and respiratory syndrome (PRRS) is caused by two species of
PRRS virus (PRRSV-1 and -2; Betaarterivirus suid 1 and 2, respectively, order Nidovirales,
family Arteriviridae) [1]. PRRSV are enveloped, single-stranded, positive-sense RNA viruses
with a tropism for porcine cells of monocyte/macrophage lineage [2]. PRRSV initially
infects alveolar macrophages [3], and replication in the lungs is important for aerosol
spread through respiratory secretions [4]. PRRSV are highly infectious, with only 10 virions
required to experimentally infect pigs [5]. PRRS continues to be one of the most eco-
nomically significant swine diseases globally. A recent estimate of the annual cost due
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to PRRS in the USA alone was US $664 million [6]. Reproductive disease incurs a large
portion of the cost due to abortions and/or the birth of weak piglets. Although respiratory
symptoms associated with PRRSV may not cause mortality, they affect growth and sales
weight. Both species of PRRSV are rapidly evolving, and highly pathogenic strains emerge
sporadically [7–10], which poses a major ongoing threat to the swine industry worldwide.
Currently, the control of PRRS is best achieved through a combination of vaccination
and biosecurity measures, such as segregation and disinfection. However, the aerosol
transmission of PRRSV has been demonstrated experimentally. It is becoming more widely
accepted as a common route of transmission, including for farms to become re-infected
following the elimination of PRRSV from a herd [11–14]. Although air filtration systems
do not eliminate the risk of new virus introductions, they can limit the spread. US pig
farms not equipped with an air filtration system were eight times more likely to experience
a PRRS outbreak than farms that used air filtration [15]. It was also estimated that sow
farms that utilized air filtration could produce 5927 more pigs per year than an unfiltered
farm, using a model of a hypothetical 3000 sow farm [16]. A four-year study comparing
the efficacy of commercial air filters, including mechanical fiberglass, antimicrobial and
electrostatic mechanical fiberglass filters, showed that all prevented the spread of PRRSV
from infected to susceptible pig populations [17]. Air filtration systems appear to be
a highly effective PRRS control tool, but they may be expensive to install and operate,
needing to be replaced often [18]. This is not optimal, especially for smaller farms, and an
air-filtration system with antimicrobial filter pads doped or impregnated with antiviral
nanoparticles (AVNP) could provide a cost-effective approach [19,20].
AVNP and antimicrobial nanomaterials have been shown to possess a range of biomed-
ical functionalities [21–24]. AVNP with intermetallic/multi-elemental compositions have
shown to actively counteract a range of bacterial pathogens [25,26], H5N1 and H1N1 in-
fluenza A viruses and the severe acute respiratory syndrome coronavirus (SARS-CoV) [27].
In addition, these nanoparticles can act at low concentrations in suspensions under the
environmental water threshold level (<100 ppm) [28,29]. AVNP represent prime candidates
for impregnation into fibers [19] and the development of air filtration systems to aid in the
control of PRRSV. As a critical first step, this study aimed to investigate the antiviral efficacy
of AVNP against PRRSV, utilizing liquid suspensions. From an initial screening of five
AVNP, three were selected for further study. A potent and rapid antiviral action of a novel
intermetallic-carbon complex nanoparticle (AVNP2) and copper nanoparticles (CuNP)
were characterized. We also demonstrated a broader antimicrobial effect of this AVNP
against Staphylococcus aureus, a Gram-positive bacterium prevalent in pig populations
globally and of public health importance.
2. Materials and Methods
2.1. Antiviral Nanoparticles (AVNP)
Antiviral nanoparticle second-generation (AVNP2), copper oxide nanoparticles (CuONP),
zinc oxide nanoparticles (ZnONP), and tungsten carbide nanoparticles (WCNP) were pro-
duced using a Tesima™ thermal plasma technology [30–32] from QinetiQ Nanomaterials
Ltd., Farnborough, UK. AVNP2, developed by the UK Antiviral Nanoparticles Consortium,
is composed of an sp2 hybridized graphitic carbon and W-Ag-Cu metallic complex, man-
ufactured for an antiviral purpose and customized for bioengineering applications [27].
Both AVNP2 and CuONP have spherical shapes. The average particle size range of AVNP2
and CuONP were between 10–20 nm and 10–70 nm, respectively. WCNP are hexagonal in
shape with an average hydrodynamic diameter of 250 nm. Elemental copper nanoparticles
(CuNP) were purchased from CF Nanotechnology (Suzhou, China). All the raw AVNP
materials used in this study were further analyzed by scanning electron microscopy (SEM)
prior to the preparations of AVNP suspensions for in vitro evaluation. Representative SEM
micrographs of WCNP, AVNP2, CuNP, CuONP, and ZnONP are shown in Supplementary
Figures S1–S5, respectively. The engineered WCNP showed no antiviral/antimicrobial
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effect against both virus (PRRSV) and bacteria (S. aureus) at the concentrations tested. They
were treated as an additional negative control in this study.
Antiviral/bacterial assays required all AVNP to be in suspension form by dispersing
into saline, PBS, or water at an initial concentration of 1.0% (w/v). All AVNP suspensions
were prepared by sonication to disperse each powder into an aqueous medium with an
on/off pulse program at 53% working power applied to each sonication process. The
sonication device was a 750 W high-frequency liquid processor (Sonics & Materials, New-
town, CT, USA). All materials were sonicated for 2–3 min until well-dispersed suspensions
were formed.
2.2. PRRSV Propagation and Titration
The PRRSV-1 subtype 1 strain Olot/91 was kindly provided by Dr. Jean-Pierre
Frossard, Animal and Plant Health Agency, Addlestone, UK. The virus was propagated
in MARC-145 cells cultured in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with sodium pyruvate, GlutaMAX, 100 U/mL penicillin, 100 µg/mL streptomycin,
and 10% fetal bovine serum (all Thermo Fisher Scientific, Loughborough, UK) (cDMEM).
PRRSV infectious titers were determined by 10-fold serial dilution of viruses, added to
96 well flat bottom tissue culture plates containing 5 × 103 MARC-145 cells/well. The
plates were incubated at 37 ◦C with 5% CO2 for 3 days. Immunoperoxidase staining was
performed to determine the number of infected wells and allow calculation of the median
50% tissue culture infective dose (TCID50) [33]. PRRSV was detected using nucleocapsid
protein-specific monoclonal antibody 1AC7 (Ingenasa, Madrid, Spain), followed by the
addition of rabbit anti-mouse immunoglobulin HRP conjugate (Thermo Fisher Scientific,
Abingdon, UK) and staining visualized by the addition of DAB substrate (Sigma Aldrich,
Poole, UK).
2.3. Assessment of Antiviral Activity of AVNPs against PRRSV In Vitro
Freshly prepared suspensions of AVNPs in PBS serially diluted 10-fold in cDMEM
were added to an equal volume of the stock suspension of PRRSV and incubated at room
temperature for 1 h with vortexing every 5 min. The same treatment of the virus with
PBS was included as a negative control. PRRSV/AVNP mixtures were then centrifuged
for 4 min at 3000× g at room temperature to pellet AVNP. A log10 dilution series of the
supernatant was created, which was then added to triplicate wells in a 96 well plate seeded
with MARC-145 cells and infectious titers determined as described above. An experiment
was additionally performed by varying the incubation time of the virus with AVNPs,
from 60 to 30, 15, 7.5, 5, 2.5, and 1.5 min. A final experiment utilized the supernatants
from suspensions of AVNPs (prepared by centrifugation after 1 h incubation at room
temperature) and incubated with PRRSV to assess antiviral activity, as described above.
2.4. Assessment of AVNP Cytotoxicity
AVNP suspensions were serially diluted in cDMEM and added to MARC-145 cells
in 96 well white-walled plates (Fisher Scientific, Loughborough, UK). After 24 h incuba-
tion, cytotoxicity was assessed using the CellTiter-Glo® Luminescent Cell Viability Assay
(Promega, Southampton, UK). Following the addition of substrate, luminescence was
measured using a CLARIOstar multilabel plate reader (BMG LabTech, Aylesbury, UK).
2.5. Inductively Coupled Plasma Atomic Emission Spectroscopy Sample Preparation and
Elemental Analyses
All labware was acid washed overnight with 4 M nitric acid prepared from 70% nitric
acid (Fisher Scientific, Loughborough, UK) and rinsed thoroughly with deionized water
before use. For ion release measurements (AVNP leaching analysis), 20 mL of dispersed
nanoparticle suspensions in (1 mg/mL, 1000 ppm) were left standing at room temperature
for 24 h when the clear settlement of nanoparticles was observed. Then, 1 mL of the
supernatants from each sample were collected and filtered using 0.22 µm sterile syringe
filters (Millipore MillexTM, Thermo Fisher Scientific, Abingdon, UK) prior to analysis
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using a Varian 710 Inductive Coupled Plasma-Optical Emission Axial Spectrophotometer
(ICP-OES; Varian, Frankfurt, Germany) equipped with a SeaSpray Nebulizer. Emission
intensities of three different wavelengths from both Ag (λ = 241.318, 328.068, 338.289 nm)
and Cu (λ = 231.598, 324.754, 327.395 nm) were detected, technical and software triplicates
were obtained from each AVNP sample. Ag and Cu content in supernatants were fully
quantified against external calibration curves standardized using TraceCert® analytical
grade standards for ICP (Sigma-Aldrich GmbH, Schnelldorf, Switzerland) with a weighted
regression. The relative Ag/Cu concentrations (in ppm) were then calculated using the
formula y = mx + c. Fully digested raw powders of AVNP that showed significant antiviral
activity (AVNP2, CuNP, and CuONP) were subjected to full metal trace elemental analysis
using ICP-OES (Supplementary Figures S12–S15).
2.6. Dynamic Light Scattering (Zeta Potential & Nanoparticle Tracking Analysis)
Zeta potentials were measured using a Nano ZS Zetasizer (Malvern Panalytical,
Malvern, UK) at 25 ◦C using a standard operation protocol for the AVNP samples. Aqueous
suspensions of each nanoparticle stock (0.1% w/v) were dispersed in water as previously
described. Selected concentrations (10, 50, and 100 ppm) of each AVNP sample were freshly
prepared prior to loading into a plastic cuvette (Malvern Panalytical). Each nanoparticle
analyte was measured in triplicate. Nanoparticle tracking analysis (NTA) was performed
using an LM10 NanoSight Instrument (Malvern Panalytical) equipped with a green laser
source (λ = 532 nm) and a CMOS camera. Each nanoparticle dispersant was directly loaded
into a sample guard; individual particles were detected using a static method. Brownian
motion of the nanoparticles in aqueous suspension was recorded in real-time at 21 ◦C. The
conditions for each analysis were optimized by adjusting the camera shutter, gain, and
laser power. Each tracking analysis was captured using in-built software (NTA 3.2 Dev
Builds 3.2.16) and was collected for 30 s in triplicate.
2.7. Surface Morphology Observation Using Scanning and Transmission Electron Microscopy
The surface morphologies of nanomaterials were analyzed using SEM and trans-
mission electron microscopy (TEM). Prior to the preparation of AVNP suspensions, the
morphology of nanomaterials was observed using SEM (JEOL JCM-5700, Tokyo, Japan). All
SEM samples were dried under vacuum and coated with 2–3 nm of gold using an Emitech
SC7620 Sputter (Quorum Technologies, Laughton, UK) prior to the image acquisitions.
All images were collected and processed using an in-built software within the instrument.
TEM images of CuNP, AVNP2, CuONP, and ZnONP samples were acquired using a JEOL
JEM-1400 instrument (Tokyo, Japan) operating at 200 kV (Supplementary Figures S6–S11).
For this study, nanopowders were sonicated first in 1 mL of ethanol, and then two drops of
the suspension were placed on 200 mesh copper grids with Formvar and carbon supports
(Agar Scientific Ltd., Essex, UK). Each sample’s excess solvent was removed under reduced
pressure (10 mmHg) prior to TEM image acquisition.
2.8. Assessment of the Minimum Bactericidal Concentration of AVNP
A Staphylococcus aureus isolate (SA2; NCTC 178582), a methicillin-resistant (RC1; NCTC
12493), and a methicillin-susceptible S. aureus strain (SC1; NCTC 12981) were obtained from
the University of Surrey Strain Collection (Guildford, UK) and cultured aerobically on brain
heart infusion (BHI) agar (Sigma Aldrich, Poole, UK) at 37 ◦C for 24 h. AVNP suspensions
were serially diluted 2-fold in Mueller-Hinton broth (MHB; Sigma) (1–0.007%) and added
to 96 well plates containing an equal volume of MHB and 1 × 105 colony forming units (cfu)
of S. aureus. Plates were incubated at 37 ◦C, aerobically in a shaking incubator at 150 rpm
for 24 h. Following incubation, a 20 µL aliquot of each sample was plated out onto MH
agar and incubated at 37 ◦C, aerobically for 24 h before assessment of bacterial growth. The
minimum bactericidal concentration (MBC) was determined as the lowest broth dilution of
AVNP, which prevented S. aureus growth on the agar plate. To assess the effects of AVNP
concentration on S. aureus growth over time, suspensions of AVNP (diluted from 0.03%,
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0.015% and 0.007% (w/v) to avoid impairments with spectrophotometry readings) and S.
aureus were incubated as described above, and optical density (600 nm) measured after 0, 8,
16 and 24 h using a Spark multimode plate reader (Tecan, Männedorf, Germany).
2.9. Statistical Methods
One- or two-way ANOVA’s with Dunnett’s or Tukey’s multiple comparison tests with
a 95% confidence interval were performed in GraphPad Prism v7.01 (GraphPad, La Jolla,
CA, USA) to statistically analyze the data (viral titer data were log10 transformed prior to
statistical analysis).
3. Results
3.1. Evaluation of the Antiviral Activity of AVNP against PRRSV
Independent assays were performed measuring the activity of a panel of AVNP (CuNP,
AVNP2, CuONP, ZnONP, and WCNP) against PRRSV. The effects of pre-treatment with
AVNP suspensions at 1, 0.1 and 0.01% (w/v) for 1 h at room temperature on the infectious
titers of PRRSV-1 Olot/91 strain were assessed (Figure 1a). The virus was undetectable
following exposure to CuNP at both 1.0 and 0.1% (w/v) concentrations, whereas the mean
titer of virus recovered following treatment with 0.01% (w/v) CuNP was 103.54 TCID50/mL.
Compared to the mean titer of the control PBS treatment (106.36 TCID50/mL), this equated
to a >48,658-fold reduction in infectious titer for both 1.0 and 0.1% (w/v) (p < 0.001) and
a 659-fold reduction for 0.01% (w/v) (p < 0.01). Treatment with AVNP2 was also highly
effective with a clear dose-dependent effect. Mean virus titers following treatment with
1.0, 0.1, and 0.01% (w/v) AVNP2 were 101.61, 103.07, and 105.19 TCID50/mL (representing a
55,199, 1929 [both p < 0.001] and 15 [p < 0.05] fold reductions, respectively). Exposure of
virus to CuONP led to a less pronounced dose dependent reduction in viral titer; with 1.0,
0.1, and 0.01% (w/v) reducing titers to 102.08 TCID50/mL (18,714-fold reduction; p < 0.001)
104.72 TCID50/mL (48-fold reduction; p < 0.05) and 106.31 TCID50/mL (2-fold reduction),
respectively. Treatment of PRRSV with ZnONP and WCNP did not produce a significant
reduction in titer when compared to the PBS control at any concentration tested.
Further assays were performed to confirm the efficacy of CuNP, AVNP2, and CuONP
against PRRSV and suspensions were further diluted (1.0, 0.1, 0.01, and 0.001% (w/v)
to titrate out the antiviral activity Figure 1b. Compared to the WCNP and PBS control
treatments, 1.0% (w/v) suspension of CuNP, AVNP2 and CuONP all caused a significant
reduction in PRRSV titers (p < 0.05). However, the difference between AVNP2 and CuNP
at 1.0% (w/v) was not significant, both AVNP2 and CuNP produced a greater reduction
in viral titer compared to CuONP (p < 0.0001). At a concentration of 0.1% (w/v), only
CuNP and AVNP2 significantly reduced viral titers (p < 0.05), with CuNP producing the
lowest viral titer of the two (CuNP: 101.86 TCID50/mL and AVNP2: 104.28 TCID50/mL;
p < 0.0001). The CuONP treatment condition at 0.1% (w/v) did not differ from the control
treatments. Compared to the control and both AVNP2 (105.35 TCID50/mL) and CuONP
(106.05 TCID50/mL), CuNP produced a significantly lower viral titer of 102.2 TCID50/mL at
0.01% (w/v) (p < 0.0001). All particles at 0.001% (w/v) were ineffective at reducing viral
titer (p > 0.05).
To assess how quickly AVNP can exhibit their effect against PRRSV, 1% (w/v) suspen-
sions were evaluated with seven different incubation times, as shown in Figure 1c. The two
most effective particles, CuNP and AVNP2 exhibited the same antiviral effect at all incuba-
tion times tested (1.5, 2.5, 5, 7.5, 15, 30, and 60 min), both nanoparticles reducing titers to
below the assay’s limit of detection (<101.55 TCID50/mL). CuONP produced titers ranging
between 103.38–104.72 TCID50/mL, which were comparable between incubation periods.
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Figure 1. Assessment of the antiviral activity of AVNP against PRRSV. (a) PRRSV-1 Olot/91 was
exposed to AVNP suspensions at 1.0, 0.1 and 0.01% (w/v) concentrations for 1 h at room temperature.
PRRSV treated with PBS served as a negative control. After removal of the AVNP, infectious virus
titers (TCID50) were obtained. Mean data ± SD from two-three independent assays is shown. (b) The
three most effective AVNP (CuNP, AVNP2, and CuONP) were further titrated, alongside WCNP and
PBS as negative controls. Mean data ± SD from four independent assays is shown. (c) The effect of
incubation time on the antiviral activity of CuNP, AVNP2, and CuONP at 1% (w/v) concentration
was assessed at 7 different times ranging from 1.5–60 min. Single technical replicates are shown for
each time point. Horizontal dashed lines indicate the limit-of-detection (LoD) of the assays.
3.2. Investigation of the Possible Interaction between AVNP and PRRSV
We hypothesized that virus destruction occurred due to ions released from AVNP
in suspensions. Thus, an experiment was conducted to compare the antiviral activity of
AVNP supernatants (containing proposed ions) against the particles (Figure 2a). Incubation
of PRRSV with each of the three AVNP (CuNP, AVNP2, and CuONP) at 1.0% (w/v)
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concentration resulted in significantly reduced viral titers (p < 0.01) compared to incubation
of virus with the comparable AVNP supernatants or the WCNP and PBS controls. CuNP
and AVNP2 supernatants slightly reduced viral titers, but this was not significantly different
from the negative controls (p > 0.05). Thus, it appears that direct contact is necessary to
mediate the anti-PRRSV activity of the selected AVNP.
Figure 2. Assessment of the requirement for direct contact to mediate the antiviral activity of selected AVNP. (a) Supernatants
from 1.0% (w/v) CuNP, AVNP2, and CuONP suspensions (incubated aerobically for 1 h at room temperature) were prepared
by centrifugation and compared alongside 1.0% (w/v) AVNP suspensions for their ability to inactivate PRRSV-1. WCNP
served as the negative control. AVNP suspensions/supernatants were incubated with the virus for 1 h at room temperature
before centrifugation and determination of infectious virus titers (TCID50). Mean data ± SD from three technical replicates
is shown. A horizontal dashed line indicates the limit-of-detection (LoD) of the assay. (b) The cytotoxicity of AVNP and
suspension supernatants were additionally assessed by addition to MARC-145 cell cultures and assessment of cell viability
after 24 h. Data are presented as the mean % viability ± SD (calculated using the control PBS treatment condition as 100%)
for technical triplicate treatments.
To assess whether direct contact with AVNP would exert cytotoxic effects, MARC-145
cells were cultured with serial dilutions of AVNP (CuNP, AVNP2, CuONP, and WCNP)
or their supernatants and toxicity assessed, as shown in Figure 2b. Percentage viability
for each treatment was calculated using values from the PBS control wells as 100%. There
was little variation in the dose-dependent toxicity between CuNP, AVNP2, and CuONP
treatments, with an average of 6.3% viability at 0.01% (w/v) concentration (10 ppm) to an
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average of 81.7% viability at the lowest concentration (0.00000244%; 0.024 ppm). When
comparing these values with that of the negative control AVNP sample (WCNP super-
natant), higher concentrations (0.01%, 0.0025%, and 0.000625%) of CuNP, AVNP2, and
Cu0NP were significantly toxic (p < 0.0001). At 0.000156% (w/v) (1.56 ppm) and 0.0000391%
(w/v) (0.391 ppm) concentrations, only CuNP and AVNP2 remained statistically different
from the control (p < 0.01). However, at the two lowest concentrations tested, all three
AVNP were not significantly different from the PBS or WCNP controls (p > 0.05). The
supernatants from all the AVNP exhibited little cytotoxic effect, the only significant data
arose from AVNP2 and CuONP supernatants tested at 0.01% (w/v) (100 ppm), deeming
these preparations cytotoxic compared to the control (p < 0.05).
To understand the insufficient antiviral effects produced by the AVNP supernatants
Figure 2, the presence of saturated ions and, hence, the metallic trace ions (Cu and Ag)
leached from bare AVNPs, were examined by ICP-OES using a fully quantitative method.
As shown in Figure 3a, the leaching properties of CuNPs, AVNP2, and CuONPs at concen-
trations of 0.1% (w/v) (1000 ppm) were assessed by measuring the metal content released
into two different types of aqueous supernatants (saline and water). In saline, AVNP2
released the highest concentration of Cu (2.54 ppm), followed by CuONP (1.59 ppm) and
negligible release from CuNP (0.06 ppm). In contrast, Cu release in water was the greatest
from CuONPs (4.06 ppm), followed by AVNP2 (1 ppm) and CuNPs (0.66 ppm). As ex-
pected, Ag release was only detected from the AVNP2 samples with a higher concentration
in the saline suspensions than water (0.5 ppm vs. 0.16 ppm, respectively). To rule out
the physiochemical involvement of the corresponding antiviral activity, pH values of the
three effective AVNPs (AVNP2, CuNPs, and CuONPs) suspensions were measured at
various concentrations (10, 50, and 100 ppm), and all were found to be near the pH neutral
(pH 7.0 ± 0.7) Figure 3b.
Figure 3. Investigation of the leaching and ionic properties of AVNP2, CuNPs, and CuONPs. (a) Ag and Cu present in
AVNPs supernatants were fully quantified against standardized calibration curves with a weighted regression by ICP-OES.
(b) The pH level of AVNP suspensions were measured at different concentrations (10, 50, and 100 ppm).
As the antiviral effect appeared to involve direct particle interactions, further mor-
phological analyses were performed using TEM and DLS to understand how the physical
properties of raw AVNP in their solid states and their hydrodynamic behavior in aqueous
states may attribute to their interaction with PRRSV. Nanoparticle tracking analysis (NTA)
was used to capture the dynamic light scattering of AVNPs (CuNP, AVNP2 and CuONP)
suspended in water. As shown in Figure 4a–c, the resultant DLS from AVNPs suspensions
were recorded and quantified to give numerical information of the nanoparticles’ hydrody-
namic sizes and concentrations (particles/mL). The average hydrodynamic sizes of all three
AVNP were found to be similar, mainly ranging from 25–275 nm. However, larger particles
could be seen in the CuNP suspension ranging between 325–525 nm. Although the NTA
real-time images suggested both AVNP2 (Figure 4b insert) and CuONP (Figure 4c insert)
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suspended well under aqueous conditions, they both appeared to be rather aggregated
compared to the aqueous CuNP sample Figure 4a insert.
Figure 4. Investigation of the hydrodynamic behavior of AVNP in aqueous suspensions (left column) and morphology
of AVNP at solid states (right column). (a–c) shows the hydrodynamic sizes, distributions, and concentrations of CuNP,
AVNP2, and CuONP suspensions at 500 ppm, obtained from by DLS study using a nanoparticle tracking analyzer (NTA).
The histograms illustrate the numbers of particles per mL (±SD) plotted against particle size distribution ranging from
0–525 nm, whilst the corresponding inserts show images of the hydrodynamic dispersive behavior of individual AVNP in an
aqueous medium captured in real-time. (d) shows bright-field TEM images of bare CuNP with some clear rectangular/cubic
crystal shapes. (e,f) shows the dark field TEM images of both AVNP2 and CuONP, which demonstrated the presence
of crystallinity within the bare samples. The inserts in (e,f) showed the corresponding bright-field image of AVNP2 and
CuONP at a higher magnification. Enlarged bright and dark field TEM images of AVNP are shown in Supplementary
Figures S5–S9.
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TEM images of the dry CuNP, AVNP2, and CuONP nanopowders provided details
of the shapes and sizes of the tested AVNP. They revealed the presence of crystallinity
in the AVNP and CuONP samples. These can be seen in Figure 4e,f, where bright spots
demonstrated crystalline strongly diffracted in the dark field mode during TEM image
acquisitions. These observations were in line with their manufacturing methods in which
the AVNP2 and CuONP were engineered through a complete vaporization top-down
process. The process uses high-temperature plasma to vaporize all microscale particles and
condenses the metal gases in the processing downstream to form nanoparticles involving
a recrystallization formation. As no crystalline structure was found in CuNP, images in
Figure 4d only show the TEM results in bright field mode. The crystallinities of AVNP2
and CuONP have been discussed previously [30,34].
The surface charge (zeta potential in mV) of each effective AVNP at a concentration of
50 ppm was analyzed using a Zeta-sizer (another DLS technique). It was found that both
CuNP and AVNP2 had negative surface charges at −9.27 (±2.68) and −20.63 (±1.9) mV,
respectively, whereas CuONP showed a positive surface charge of +8.4 (±0.66) mV.
3.3. Assessment of the Antimicrobial Activity of Selected AVNP against S. aureus
As a final element to this study, the utility of the selected AVNP was assessed further
by evaluating their activity against the bacterium S. aureus. Methicillin-resistant S. aureus
(MRSA) occurs widely in pig populations globally, and while colonization alone does not
cause disease in pigs, it is of great public health importance [35,36]. AVNP2, CuNP, and
CuONP all showed bactericidal activity against the three S. aureus strains tested, whilst
WCNP showed no bactericidal effect at any of the concentrations tested. For comparison
to AVNP2, CuNP, and CuONP, the minimum bactericidal concentration (MBC) of WCNP
was given a nominal value of 1, as shown in Figure 5a. CuNP showed the lowest MBC,
displaying complete inhibition of growth at 0.17%, 0.25%, and 0.42% (w/v) for the three
test S. aureus strains, which were significant compared to WCNP (p < 0.0001). AVNP2
showed significant growth inhibition against the three strains with an MBC of ~0.5% (w/v)
(p < 0.001). CuONP also exhibited clear antimicrobial activity against all three strains,
MBC of 0.25%, 0.42%, and 0.5% (w/v) (p < 0.001). In contrast to the antiviral activities, the
differences in MBC between AVNP2, CuNP, and CuONP were not statistically significant.
AVNP inhibition of bacterial growth was assessed by estimating bacterial concentration
by measuring optical density (OD) at 600 nm Figure 5b. AVNP suspensions were tested
at 0.03% (300 ppm), 0.015% (150 ppm), and 0.007% (w/v) (70 ppm) since higher particle
densities impaired OD measurements. CuNP and CuONP suspensions both significantly
reduced bacterial growth (p < 0.001 and p < 0.05, respectively), whereas AVNP2 did not.
CuNP at 0.03% (w/v) significantly reduced growth as measured at 8 and 24 h (p < 0.01)
and at 0.07% (w/v) only reduced growth at 8 h (p < 0.01). Other AVNP suspensions did not
show significant reductions at individual time points (p > 0.05).
4. Discussion
This study has shown that CuNP and AVNP2 possess potent antiviral activity against
PRRSV. Results consistently showed a >99.9% reduction in virus titer, which is commonly
considered the required level of reduction for an effective disinfectant. Nevertheless, CuNP
particles were more efficient at lower concentrations than AVNP2, in line with previous
literature finding copper-based nanoparticles to be a particularly effective antimicrobial [30].
CuNP also showed the most effective antimicrobial activity against S. aureus. Our previous
study showed that whilst CuNP showed a good antimicrobial effect against Gram-positive
S. aureus and Gram-negative Pseudomonas aeruginosa, a more pronounced effect was seen
with multi-elemental nanoparticles, such as AVNP2 [26]. But this did not translate into
antiviral activity against PRRSV. On investigating the contact time required for PRRSV
destruction, it was found that AVNP2 and CuNP can have their full effect after just
1.5 min of incubation at room temperature. However, further research is required to test
even shorter incubation times to clarify the minimum contact time required for virucidal
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activity. This would be an important factor for consideration if they were to be applied in
filtration systems.
Figure 5. Assessment of the antimicrobial activity of selected AVNP against S. aureus. (a) The minimum bactericidal
concentration (MBC) (% w/v) of AVNP2, CuNP, CuONP, and WCNP was determined against three S. aureus strains (SA2,
SC1, RC1). Mean data ± SD from three independent assays is shown. (b) The inhibition of S. aureus growth (strain RC1) in
the presence of 0.03% (w/v), 0.015% (w/v) and 0.007% (w/v) suspensions was assessed over time. Mean data ± SD for the
three S. aureus strains collected in two independent experiments are shown.
Past research has suggested that viral or bacterial destruction could result from ions
released from metallic nanoparticles [28–30]. However, results from the assay directly
comparing the antiviral activity of particles and their supernatants showed that AVNP2,
CuNP, and CuONP particles were far more effective at destroying PRRSV than their own
supernatants. ICP-OES analysis showed these AVNP to be rather inert; only an average
of 0.13% of active ions was found to have saturated into the corresponding aqueous
supernatants. Thus, the lack of active ion presence in the AVNP supernatants would explain
the supernatant experiments’ low effects for both antiviral and cytotoxic activity. Moreover,
the low ionic concentrations of the CuNP supernatant (0.06−0.66 ppm) also suggested that
strong antiviral effect observed was not related to the ionic interactions between CuNP and
PRRSV. PRRSV is inactivated by acidic conditions [37], but AVNP suspensions presented a
near-neutral pH, ruling this out as an explanation for the antiviral activity.
As the observed antiviral effects of all three AVNP (CuNP, AVNP2, and CuONP)
involved direct ‘particle-virus’ interactions, the initial mode of contact would involve
the surface of the AVNP and the PRRSV virion. Therefore, we next analyzed the AVNP
themselves. The DLS analysis showed evidence of mono-dispersibility of CuNP in an
aqueous state that may have increased chances of NP exposure. It provided a high surface
contact level with PRRSV, which led to an enhanced antiviral effect. It is worth noting
that once CuNP was dispersed into an aqueous medium, and it was expected to slowly
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oxidize into cuprous oxide (Cu2O), which is a highly reactive species with cytotoxic and
antiviral activity [38,39]. Zeta potential measurements found that both CuNP and AVNP2
had negative surface charges, whereas the less effective CuONP showed a positive surface
charge. Hence, the negatively charged CuNP and AVNP2 may be statically attracted to the
PRRSV virion, leading to more effective virion destruction. A similar explanation had been
reported elsewhere [34].
In summary, this study has demonstrated the potent ability of AVNP2, CuONP, and
CuNP in the liquid phase to inactivate PRRSV and, to a lesser extent, S. aureus. Evaluation
of AVNP physicochemical properties provided data that may partly explain the toxicity
of these particles to viruses, bacteria, and mammalian cells. These data enabled the
selection of AVNP as candidate nanoparticles for further evaluation, which will involve
the preparation of hybrid AVNP embedded polymer fibers [19]. Retention of efficacy at
solid/gas interfaces would enable the development of novel antimicrobial air-filtration
systems to reduce transmission of PRRSV and other airborne pathogens.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/nano11082120/s1, Figure S1. SEM image of WCNP.; Figure S2. SEM image of AVNP2.;
Figure S3. SEM image of CuNP.; Figure S4. SEM image of CuONP.; Figure S5. SEM image of
ZnONP.; Figure S6. TEM image of CuNP (bright field).; Figure S7. TEM image of CuONP (bright
field).; Figure S8. TEM image of CuONP (dark field).; Figure S9. TEM image of AVNP2 (bright
field).; Figure S10. TEM image of AVNP2 (dark field).; Figure S11. TEM image of ZnONP (bright
field).; Figure S12. Elemental analysis of blank nitric acid (HNO3) sample, where each optical
emission spectrum (OES) shows the detected signal of the corresponding traced metal. As can
be seen, the blank nitric acid was found to contain Zn, Si, Ca, Mg. It is worth noting that these
signals also appeared in the subsequent results obtained from all AVNP samples (Figures S12–S14),
as nitric acid was used for the digestion process, these observed signals therefore were regarded
as blank signals.; Figure S13. Metal trace elemental analysis of fully digested CuNP using ICP-
OES. Apart from a trace of Iron (Fe), Copper was the only element detected in the fully digested
CuNP sample.; Figure S14. Metal trace elemental analysis of fully digested CuONP using ICP-
OES. The manufacturing method, morphological and antimicrobial studies of CuONP have been
previously published by Ren et al., 2009 (DOI: 10.1016/j.ijantimicag.2008.12.004).; Figure S15. Metal
trace elemental analysis of fully digested AVNP2 using ICP-OES. The composition of AVNP2 has
been previously studied, further structual characterization was published by Cheong et al., 2017
(doi:10.3390/nano7070152).
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